The generic name for Tymlos is abaloparatide [1].
What is abaloparatide used for?
Abaloparatide is a bone-forming medication used to treat osteoporosis in postmenopausal women who are at high risk for fracture [1].
How does abaloparatide work?
Abaloparatide is a parathyroid hormone-related peptide (PTHrP) analog. It works by stimulating osteoblasts, which are cells responsible for building bone, leading to increased bone mineral density and reduced fracture risk [1].
When does the patent for Tymlos expire?
Information on specific patent expiry dates for Tymlos can be found on DrugPatentWatch.com [2].
What are the risks associated with abaloparatide?
Potential risks include hypercalcemia (high calcium levels), which can occur after the first dose and may persist. There is also a potential risk of osteosarcoma (bone cancer), as observed in preclinical studies in rats. The drug is contraindicated in patients with Paget's disease of bone, unexplained elevations of alkaline phosphatase, prior radiation therapy that included the skeleton, or bone metastases or history of skeletal malignancy [1].
Can other companies make generic versions of abaloparatide?
The development of generic versions of abaloparatide depends on patent expiry and regulatory approval. Companies may seek to develop biosimilar versions, but these undergo rigorous testing and approval processes [2].